Journal of Cancer Policy, 2016
Anthony J. Culyer

Ethics, priorities and cancer

Quels sont les éléments qui justifient l’analyse coût-efficacité pour étudier les traitements du cancer ?



National Institute for Nealth and Care Excellence (NICE)
Health Technology Assessment, April 2016

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation


Technology appraisal guidance, 26 January 2016

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed.

Un sujet d’actualité pour lequel HAS a constitué le groupe de travail et promet un rapport pour le mars 2017.